With a broad research focus on heart disease risk reduction through the development of novel treatment strategies, Stephen Nicholls, MBBS, PhD, Monash University and Victorian Heart Hospital, Melbourne, Australia. discusses contributions in the space from therapies with systemwide effects.
With a broad research focus on heart disease risk reduction through the development of novel treatment strategies, Stephen Nicholls, MBBS, PhD, professor of cardiology, Monash University, and director, Victorian Heart Hospital, Melbourne, Australia, discusses contributions in the space from incretin-based therapies glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and tirzepatide, a dual GIP/GLP-1 receptor agonist. The therapies have several systemic effects, including reducing gastric emptying and hemoglobin A1c (HbA1c) and increasing insulin production and release.
Transcript
Can you describe the mechanism of the GIP hormone in promoting weight loss for patients who have tried other treatments and strategies but without success?
I think there's a range of incretin-based therapies, which are being developed for the management of type 2 diabetes, but also for weight loss. Traditionally, these therapies have targeted a factor called GLP-1 receptor, and a number of agents are already in the clinic that target GLP-1. GIP is another incretin-based therapy; it does a number of the same things that GLP does, but it has some complementary functions.
We expect these therapies will reduce food intake, will have some central nervous system effects, which will lead to weight loss. But in addition, you'll see a reduction in gastric emptying; you'll see complimentary effects on the pancreas, including increasing insulin production and release. You also see direct effects on the adipose tissue. And so while some of the effects are the same, there's other effects, which kind of are complementary, and that's why we are seeing, in these early trials, greater weight loss with a dual incretin therapy and better metabolic risk factor control.
Can you discuss the “additive effect” of GIP and GLP-1 that appears to make tirzepatide “greater than the sum of its parts” in helping patients control their A1c and lose weight?
Because we see a little bit more weight loss with tirzepatide compared to your standard GLP-1 receptor agonists, such as dilaglutide and semaglutide, you're going to see a greater improvement in metabolic risk factors. We know that there's a greater reduction in HbA1c. We see a greater proportion of patients with type 2 diabetes having reductions in HbA1c greater than 2%, we're seeing a reduction in C-reactive protein, we're seeing improvement in blood pressure and lipid parameters.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More